VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced a Research License and Exclusive Commercial Option Rights Agreement with Werfen’s Immunoassay Technology Center to assess antiphospholipid syndrome (“APS”) using Volition’s Nu.Q H3.1 Neutrophil Extracellular Traps (“NETs”) assay on Werfen platforms.
“We are proud to have entered into this agreement with Werfen, as we implement our strategy to out license our proprietary Nu.Q NETs test to large worldwide companies to leverage their knowledge of specific diseases, product development, regulatory experience and their installed base of proprietary analyzers,” said Gael Forterre, Chief Commercial Officer at Volition.
Marta Palicio, Werfen’s Immunoassay Technology Center Innovation R&D Director, commented, “We have already successfully transferred the Nu.Q NETs assay to our ACL AcuStar platform. Early results in NETs levels detection in APS patients with the Nu.Q test are encouraging. We are excited to validate further and complete a clinical utility study to determine the potential role of this marker as a risk indicator of thrombosis in APS patients, allowing a better management of this very complex syndrome. This could open the possibility to enlarge Werfen’s portfolio in APS testing.”
APS is a complex autoimmune disorder affecting around 4 million people and typically diagnosed via two positive antibody tests at least 12 weeks apart. Volition believes its Nu.Q® NETs test is the first CE-IVD biomarker being investigated in APS and could improve both decision-making and ongoing patient monitoring.
To view the full press release, visit: https://ibn.fm/B8EYn
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
The contents found at Volition’s website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
For further information, visit the company’s website at www.Volition.com
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN